2016 American Transplant Congress
Incidence and Renal Consequences of Type 2 Diabetes Mellitus in Kidney Donors.
Diabetes Mellitus (DM) continues to be the most common cause of kidney disease. The incidence of DM following kidney donation is unknown. Moreover, whether its…2016 American Transplant Congress
Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.
Background: kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is not clear how the acceptance/listing status…2016 American Transplant Congress
99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.
1UNOS, Richmond, VA; 2Univ Hosp Case Med Ctr, Cleveland, OH; 3Emory Univ Hosp, Atlanta, GA.
Background: The Kidney Allocation System (KAS), implemented on 12/4/14, increased allocation priority for candidates with CPRA of 99-100%. Analyses performed on behalf of the OPTN…2016 American Transplant Congress
Short Term Changes in HRQOL Following Kidney Transplantation.
Health-Related Quality of Life (HRQOL) is a patient-centered outcome that measures the impact of a disease and its treatment. This is particularly relevant to those…2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…2016 American Transplant Congress
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…2016 American Transplant Congress
Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation.
Functional assessment of HLA antibodies (Abs) has historically been limited to complement-based assays, which have known limitations. Moreover, HLA Abs mediate injury by complement-independent mechanisms,…2016 American Transplant Congress
Immunogenic HLA-DR Eplet Mismatches as Predictors of Transplant Glomerulopathy.
BackgroundThe number of HLA-DR eplet mismatches (eplet load) is a risk factor for the development of anti-HLA antibodies and transplant glomerulopathy (TG). In the case…2016 American Transplant Congress
Reversibility of Acute Kidney Rejection According to the Banff 2013 Classification: A Retrospective Cohort Study.
1CRCHUM, Montreal, QC, Canada; 2Statsciences, Montreal, QC, Canada; 3HMR, Montreal, QC, Canada.
Background: Vascular involvement of the allograft has classically been regarded as a poor prognostic factor in acute kidney graft rejection. Cell-mediated endarteritis often coexists with…2016 American Transplant Congress
YKL-40 Predicts Renal Recovery in Deceased-Donor Transplantation.
Background Deceased-donor kidneys with acute kidney injury (AKI) are often discarded for fear of poor transplantation outcomes. Donor biomarkers that predict post-transplant renal recovery could…
- « Previous Page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- …
- 180
- Next Page »